Internis is a pharmaceutical company engaged in the development and commercialisation of medicines aimed at the treatment and prevention of a range of common bone disorders, such as osteoporosis and vitamin D3 deficiency.
Norgine Ventures provided a venture debt facility to Internis in July 2013.
The investment in Internis Pharmaceuticals Limited was successfully exited following the acquisition of Internis by Stada Arzneimittel AG in December 2014.
Location: United Kingdom, England, North Devon
Member count: 11-50
Investors 1
| Date | Name | Website |
| - | Norgine Ve... | norgineven... |